Nurexone reports new siRNA sequences with potential for spinal cord injury

Dec. 1, 2023

Nurexone Biologic Inc. has reported results from laboratory tests of its secondary two proprietary sequences, showing promise for the treatment of spinal cord injuries.

BioWorld Science RNA Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 1, 2025.

Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal

BioWorld Science

As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive...

Corcept looks to NDA following strong phase III ovarian cancer data

BioWorld

Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The...

Marks’ departure intensifies regulatory uncertainty at US FDA

BioWorld

Peter Marks’ March 28 letter giving one week’s notice of his resignation as director of the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) is...